Smith Dawn K, Grohskopf Lisa A, Black Roberta J, Auerbach Judith D, Veronese Fulvia, Struble Kimberly A, Cheever Laura, Johnson Michael, Paxton Lynn A, Onorato Ida M, Greenberg Alan E
Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, CDC, Atlanta, Georgia 30333, USA.
MMWR Recomm Rep. 2005 Jan 21;54(RR-2):1-20.
The most effective means of preventing human immunodeficiency virus (HIV) infection is preventing exposure. The provision of antiretroviral drugs to prevent HIV infection after unanticipated sexual or injection-drug--use exposure might be beneficial. The U.S. Department of Health and Human Services (DHHS) Working Group on Nonoccupational Postexposure Prophylaxis (nPEP) made the following recommendations for the United States. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person known to be HIV infected, when that exposure represents a substantial risk for transmission, a 28-day course of highly active antiretroviral therapy (HAART) is recommended. Antiretroviral medications should be initiated as soon as possible after exposure. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person of unknown HIV status, when such exposure would represent a substantial risk for transmission if the source were HIV infected, no recommendations are made for the use of nPEP. Clinicians should evaluate risks and benefits of nPEP on a case-by-case basis. For persons with exposure histories that represent no substantial risk for HIV transmission or who seek care >72 hours after exposure, DHHS does not recommend the use of nPEP. Clinicians might consider prescribing nPEP for exposures conferring a serious risk for transmission, even if the person seeks care >72 hours after exposure if, in their judgment, the diminished potential benefit of nPEP outweighs the risks for transmission and adverse events. For all exposures, other health risks resulting from the exposure should be considered and prophylaxis administered when indicated. Risk-reduction counseling and indicated intervention services should be provided to reduce the risk for recurrent exposures.
预防人类免疫缺陷病毒(HIV)感染的最有效方法是防止接触。在意外发生性接触或注射吸毒接触后提供抗逆转录病毒药物以预防HIV感染可能有益。美国卫生与公众服务部(DHHS)非职业性暴露后预防(nPEP)工作组为美国提出了以下建议。对于在非职业性接触已知感染HIV者的血液、生殖器分泌物或其他潜在传染性体液后≤72小时寻求治疗的人,当这种接触代表有很大传播风险时,建议进行为期28天的高效抗逆转录病毒治疗(HAART)。抗逆转录病毒药物应在接触后尽快开始使用。对于在非职业性接触HIV状况不明者的血液、生殖器分泌物或其他潜在传染性体液后≤72小时寻求治疗的人,如果接触源感染HIV则这种接触将代表有很大传播风险,不建议使用nPEP。临床医生应逐案评估nPEP的风险和益处。对于接触史不代表有很大HIV传播风险或在接触后>72小时寻求治疗的人,DHHS不建议使用nPEP。临床医生可考虑为有严重传播风险的接触情况开具nPEP处方,即使此人在接触后>72小时寻求治疗,前提是他们判断nPEP降低的潜在益处超过传播风险和不良事件风险。对于所有接触情况,应考虑接触导致的其他健康风险,并在有指征时进行预防。应提供降低风险咨询和有指征的干预服务以降低再次接触的风险。